

# The Effects of Self-Management Interventions on Depressive Symptoms In Adults With Chronic Physical Disease(S) Experiencing Depressive Symptomatology: A Systematic Review And Meta-Analysis

**Lydia Ould Brahim** (✉ [lydia.ouldbrahim@mail.mcgill.ca](mailto:lydia.ouldbrahim@mail.mcgill.ca))  
McGill University <https://orcid.org/0000-0003-1638-4953>

**Sylvie Lambert**

McGill University

**Nancy Feeley**

McGill University

**Chelsea Coumoundouros**

Uppsala University: Uppsala Universitet

**Jamie Schaffler**

St Mary's Research Centre

**Jane McCusker**

McGill University

**Erica Moodie**

McGill University

**John Kayser**

CIUSSS du Centre-Sud-de-l'Île-de-Montréal

**Kendall Kolne**

Trillium Lakelands District School Board

**Eric Belzile**

St Mary's Research Centre

**Christine Genest**

Université de Montréal: Université de Montréal

---

## Research article

**Keywords:** Self-management, chronic disease, depression, anxiety, decision-making, systematic review

**Posted Date:** February 16th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-228613/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

## Abstract

**Background:** Chronic diseases are the leading cause of death worldwide. It is estimated that 20% of adults with chronic physical diseases experience concomitant depression, increasing their risk of morbidity and mortality. Low intensity psychosocial interventions, such as self-management (SM), are part of recommended treatment; however, no systematic review has evaluated the effects of depression SM interventions for this population.

**Objectives:** The primary objective was to examine the effect of SM interventions on reducing depressive symptomatology in adults with chronic disease(s) and co-occurring depressive symptoms. Secondary objectives were to evaluate the effect of these interventions on improving other psychosocial and physiological outcomes (e.g., anxiety, glycemic control) and to assess potential differential effect based on key participant and intervention characteristics (e.g., chronic disease, provider).

**Methods:** Studies comparing depression SM interventions to a control group were identified through a) systematic searches of databases to June 2018 [MEDLINE (1946 -), EMBASE (1996 -), PsycINFO (1967 -), CINAHL (1984 -)] and b) secondary 'snowball' search strategies. The methodological quality of included studies was critically reviewed. Screening of all titles, abstracts, and full texts for eligibility was assessed independently by two authors. Data were extracted by one author and verified by a second.

**Results:** Fifteen studies were retained: 12 for meta-analysis and three for descriptive review. In total, these trials included 2064 participants and most commonly evaluated interventions for people with cancer ( $n = 7$ ) or diabetes ( $n = 4$ ). From baseline to  $< 6$  months (T1), the pooled mean effect size was -0.47 [95% CI -0.73, -0.21] as compared to control groups for the primary outcome of depression and -0.53 [95% CI -0.91, -0.15] at  $\geq 6$ -months (T2). Results were also significant for anxiety (T1 and T2) and glycemic control (T2). SM skills of decision-making and taking action were significant moderators of depression at T1.

**Conclusion:** SM interventions show promise in improving depression and anxiety in those with concomitant chronic physical disease. The findings may contribute to the development of future SM interventions and delivering evidence-based care to this population. Further high-quality RCTs are needed to identify sources of heterogeneity and investigate key intervention components.

**Prospero registration:** CRD42019132215

## Background

### Prevalence and Impact of Depression in People with Chronic Disease(s)

Depression affects 300 million people and is currently the leading cause of mortality worldwide substantially impacting social and occupational functioning (1-4). Prevalence of depression is more common among individuals with chronic physical diseases (2, 3, 5). Estimates indicate that approximately 20% of people with chronic physical diseases experience depression, at least twice the rate found in the general population (5-7).

Chronic diseases are increasingly prevalent and are currently estimated to account for 60% of all deaths worldwide (8, 9). Studies have demonstrated that depression has a significant impact on the course and health outcomes of concomitant chronic physical diseases and complicates treatment overall (5, 6). For example, depression has been shown to decrease treatment adherence, amplify somatic symptoms, diminish self-efficacy of health-related behaviours (6, 10, 11). Furthermore, in addition to major depressive disorder, sub-threshold depression is associated with negative outcomes including increased morbidity in those with co-morbid physical diseases and is a risk factor for major depression (12-14).

### Self-management Interventions for Depression

It is recognized that timely treatment of depression is likely to improve functional ability, quality of life, and will considerably reduce the burden of chronic physical disease on the care recipient (15, 16). However, worldwide less than half of those affected by depression receive adequate treatment, as there is often limited care available or barriers to accessing it, particularly high cost and lack of mental health professionals (12, 17, 18). In response to the need for more depression support, one more cost-efficient option that has shown promise is self-management (SM) interventions. SM interventions for depression have been formally incorporated into many healthcare systems and are recommended in best practice guidelines (19-21). The only guidelines specifically targeting the treatment of depression in those with concomitant chronic physical disease(s), recommend SM interventions for the treatment of mild to moderate depressive symptoms or as adjunctive therapy in the case of more severe symptoms (22). However, to our knowledge, no systematic review has evaluated the effects of depression SM interventions across chronic physical disease populations.

SM refers to the tasks an individual must undertake to live well with their chronic disease(s) (23, 24). Generally, these tasks involve: a) medical management, b) maintaining, changing, or developing new meaningful behaviours, and c) dealing with the emotional impacts of the disease(s) (25). In SM, the individual's role in their own care is considered central and the individual takes on the responsibility, as much as possible, of developing the necessary skills to manage their symptoms.

SM includes more than providing health or disease-related information, rather it is focused on behaviour change through the development of the skills and confidence needed for successful SM of chronic disease (26, 27). This is usually accomplished through the use of psychoeducational or behaviour strategies (28). Learning these SM skills can be done independently or in collaboration with health care professionals (HCPs) or a non-professional, often peer, support person (25, 29).

Research to date indicates that SM involves core skills (e.g., problem-solving, decision-making) that can be applied across chronic diseases (25). Based on the literature, SM skills specific to the management of depression have been identified including behavioural activation (e.g., increasing positive activities) and social support (see Appendix A for details and references).

## Self-management, Self-help, Cognitive Behavioural Therapy, and Self-care

SM is not interchangeable with self-help, which encompasses a much broader range of interventions that are primarily self-directed (e.g., books, smartphone application). Self-help interventions are predominantly designed to limit contact with HCPs (30). On the other hand, SM interventions focus on specific skills and are often conducted in close collaboration with HCPs, although some may be self-directed (25). Though many SM interventions use principles of cognitive behavioural therapy (CBT), these are also distinct (29). A primary difference is that SM is not a form of psychotherapy and can be delivered by a variety of HCP (e.g., it is not a protected act) or as a self-directed intervention.

Finally, self-care is also frequently used interchangeably with SM; however, they may be delineated on several fronts. Self-care involves managing one's health, with or without a chronic condition. It also encompasses a broad range of strategies including 'doing nothing.' Another marked difference is that self-care does not usually involve HCP support and focuses primarily on health promotion or the prevention of disease or accident (31). In contrast, SM is one element of the Chronic Care Model, having been developed specifically for people with chronic disease and focuses on the development of evidence-based skills (25, 28, 31).

## Aims of this Review

Accounting for the issues outlined above, the primary objective of this review is to determine the effects of SM interventions on reducing depressive symptomatology among adults with chronic physical disease(s) and co-morbid depressive symptoms. The secondary objectives are:

- a. To assess the effects of SM interventions on other physiological and psychosocial outcomes (e.g., quality of life, fatigue) among adults experiencing symptoms of depression.
- b. To assess whether the interventions reviewed have differential effects on the primary outcome of depressive symptoms depending on intervention characteristics and content: the type and number of SM skills targeted, mode of delivery (e.g., face-to-face, online), type and intensity of guidance, intervention provider, format (e.g., group or individual), and duration (minutes of participation) and length of time over which the intervention was delivered.
- c. To determine whether the effects of SM interventions on the primary outcome of depressive symptoms vary depending on the participants' co-occurring chronic physical disease and baseline level of depressive symptoms (e.g., mild, moderate).

## Methods

### Methodological Framework

The methods for this review were developed following the recommendations of the *Cochrane Handbook for Systematic Reviews of Interventions* (32) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (33). The protocol was registered with the prospective register of systematic reviews (PROSPERO CRD42019132215).

### Criteria for Considering Studies for this Review

#### Types of Studies

Published or in press peer-reviewed full-text randomized controlled trials (RCTs) as well as cross-over trials and studies using a quasi-experimental design (e.g., controlled trials without randomization, but a comparison group) were considered for inclusion in this review. To be eligible, the primary outcome (depressive symptoms) had to be measured pre- and post-intervention and only English and French language articles were included. Conference abstract and theses were excluded.

#### Types of Participants and Settings

The target population for this review was adults (over age 18) with chronic physical disease(s) experiencing at least mild depressive symptoms according to a validated scale or clinical interview. These psychometrically validated questionnaires and cut-off scores indicating at least mild depressive symptoms were eligible for inclusion:

- Beck Depression Inventory (scores  $\geq 10$ ) (34, 35)
- Beck Depression Inventory-II (scores  $\geq 13$ ) (36)
- Centre for Epidemiological Studies – Depression (scores  $\geq 16$ ) (37, 38)
- Centre for Epidemiological Studies – Depression 10-item version (scores  $\geq 10$ ) (39, 40)
- Hamilton Depression Rating Scale – Depression subscale (scores  $\geq 8$ ) (41)

- Hospital Anxiety and Depression Scale – Depression (scores  $\geq 8$ ) (42)
- Patient Health Questionnaire (scores  $\geq 5$ ) (43)
- Geriatric Depression Scale (scores  $\geq 11$ ) (44)

In terms of clinical interviews, the DSM-III and above (45-49) as well as the ICD-9 and above (50, 51) were considered eligible.

Studies including participants with one or multiple chronic physical diseases were eligible as defined by the Public Health Agency of Canada (excluding dementia) and World Health Organization (9, 52). Participants taking anti-depressant medication were eligible if pharmacotherapy was not part of the intervention being evaluated. In terms of co-morbidities, studies including participants with a diagnosis of bipolar disorder, post-partum depression, seasonal affective disorder, or post-traumatic stress disorder were excluded as the etiology, disease course, and treatment recommendations for these conditions differ from depression (53-56). No limits were placed on the setting in which the study was conducted.

## ***Types of Interventions***

**Experimental Interventions.** Studies evaluating SM interventions for depressive symptoms were included. SM interventions were eligible if they included at least one of the key SM skills described in Appendix A. These skills were derived from the theoretical literature as well as from existing SM interventions from reputable (peer-reviewed or government issued) sources (25, 29, 57-59). Further, the intervention had to be administered to the individual directly. Interventions in which the person with the chronic disease participated with someone else (e.g., family member) were excluded due to the confounding effects of social support (60).

Multi-component interventions were eligible as long as the above SM criteria were met and at least one component targeted mood, distress, or depression. To avoid confounding effects, studies evaluating interventions including a pharmacological component were excluded. All formats of interventions were eligible (e.g., workbooks, online modules). Level of guidance by HCPs was not an exclusion criterion; self-directed, minimal contact, and HCP administered interventions were all eligible.

**Comparator Interventions.** Eligible control comparisons were no treatment, treatment as usual, waitlist, and attention control groups, as long as the participants were not receiving active components of the interventions (e.g., psychological therapy or the SM skills outlined in Appendix A).

## ***Outcome Measures***

The primary outcome was depressive symptoms. The secondary outcomes were a) improvement in psychosocial outcomes such as quality of life, anxiety, SM skills, and self-efficacy, b) improvement in physical health measures, c) improvement in alcohol and drug consumption, d) decrease in health care utilization.

## **Information Sources and Study Selection**

### ***Search Strategies***

Eligible studies were primarily identified through searches of electronic bibliographic databases. Secondary search strategies included: verifying the reference lists of the included full-texts and using the PubMed ‘find similar’ function. Unpublished findings were also sought through the Cochrane library as well as the national and international trial registries outlined in the *Cochrane Handbook for Systematic Reviews* (32). These were searched for relevant trial protocols and, if published findings of these trials could not be found, authors were contacted directly for further information.

### ***Database Searches***

Eligible studies were identified by searching the following databases: MEDLINE (1946-), EMBASE (1996 -), PsycINFO (1967 -), and Cumulative Index to Nursing & Allied Health (CINAHL) (1984 -). The search was conducted in June 2018 and no limits were applied. All databases were searched using a combination of keywords and subject headings across three concepts: a) SM, b) depression, and c) trial design (RCT or quasi-experimental). The search strategy was developed in consultation with a health sciences librarian and were assessed using the Peer Review for Electronic Search Strategies (PRESS) guidelines (61). The full primary electronic search for Ovid Medline is included in Appendix B. All titles and abstracts were downloaded to a citation manager, EndNote, and screened using Rayyan online software. Duplicates were removed according to the procedures outlined in Bramer, Giustini (62).

## Study Selection

Two authors independently assessed the eligibility of all retrieved titles, abstracts, and full-texts to confirm inclusion or exclusion. Two authors also separately examined the reference lists of included full texts. Finally, searches were conducted using the 'find similar' function of PubMed. Any disagreements were discussed with a third author until consensus was established. Multiple reports relating to the same study were aggregated so that findings reflected each study rather than each report.

## Data Extraction

Data were extracted using a standardized Microsoft Excel form that was developed based on the *Cochrane Handbook for Systematic Reviews* (32). The form was adapted from one used in a previous systematic review conducted by team members (63, 64). Data were extracted by one author and confirmed by at least one other. Disagreements were discussed with a third author until resolved.

The following data on study characteristics were extracted: citation details, country of origin, study design, aims, theoretical framework, population (age, diagnosis, gender, depressive symptoms), sample size, setting (source of recruitment), summary of intervention and control groups, SM skills in the intervention, format of the intervention, intervention provider, level of guidance, duration of the intervention (number of minutes of participation), length of intervention (time period over which the intervention was delivered, e.g., 2-months of sessions), monitoring of fidelity and adherence, outcomes, timing of measurement, and attrition (32). Outcomes were grouped into three time periods: T1 from baseline < 6-months post-baseline and T2 ≥ 6-months post-baseline. If any data were missing or unclear, the authors of the manuscript were contacted for further information.

## Methodological Quality

Two authors independently assessed the risk of bias of each study based on the criteria outlined in the Cochrane Risk of Bias tool (65). Again, disagreements were discussed with a third author until consensus was reached. The risk of bias was evaluated according to the following criteria: a) inclusion criteria specified, b) pre-specified primary outcome(s), c) psychometric properties of primary outcomes provided, d) explicit power calculation, e) target sample size reached, f) appropriate randomization procedures and allocation concealment, g) discussion of potential co-interventions, h) baseline characteristics of all groups provided, i) blinding of outcome assessors, participants, and interventionists, j) adherence to intervention (>75%), k) fidelity monitoring, l) management of missing data (intention-to-treat analysis), m) participant retention (> 80%), and n) reasons for attrition stated.

Each potential source of bias was evaluated as having been met (score 1) or not met (score 0). If the information was not specified in the manuscript the authors were contacted. If the information could not be clarified, the item was considered not met. Studies were considered to be of high methodological quality if 13-17 of the criteria were met, moderate quality if 8-12 were met, and low fewer than 8 were met. Direct quotes from each study as well as supporting comments were included in the evaluation of each study. For evidence of selective reporting, study protocols or trial registration of included articles, when available, were compared to the published findings and unexplained discrepancies were noted (65).

## Data Analysis

Effect sizes (Hedge's adjusted  $g$ ) was calculated using outcome scores at post-intervention assessment between treatment and control conditions for the T1 and T2 time periods (32, 66). Hedge's adjusted  $g$  was selected to reduce potential bias due to small sample sizes (67). The magnitude of the effect size can be interpreted according to the benchmarks outlined by Cohen (1988) (68); namely, small (0.2), moderate (0.5), and large (0.8).

Pooled mean effect sizes were calculated to obtain a summary statistic for the T1 and T2 periods. If a study reported both per protocol and intention-to-treat analyses, per protocol data was included in the meta-analysis. The Higgin's statistic ( $I^2$ ) was calculated to measure the heterogeneity across studies with 0% indicating no heterogeneity, 25% low, 50% moderate, and > 75% high heterogeneity (65). It was anticipated that there would be considerable heterogeneity across studies arising from differences in the interventions delivered, sample characteristics, and study designs. As such, a random effects model was used for meta-analysis calculation. As the number of studies was small, in addition to the DerSimonian-Laird approach, the Knapp-Hartung approach was used to make small-sample adjustments to the variance estimates of any outcomes that were statistically significant (69). This more conservative approach produces a wider confidence limit appropriate when the sample size is small (69). All tests were two-sided, and the significance level was set at  $p < 0.05$ . These analyses were conducted using RevMan 5.3.

Publication bias was evaluated through inspection of funnel plots of the primary outcome variable of depression (32). The effect of potential moderators on the primary outcomes was also assessed (70). The prespecified moderators, participant and intervention characteristics, are detailed in Table 3. Studies were separated into sub-groups based on these variables and meta-regressions were performed to identify whether there was a statistically significant difference in

outcomes between the sub-groups. There is no consensus on the number of studies required to run a meta-regression; these were performed when sub-groups included 4 or more studies (p-value < 0.05 was set to establish significance) (71). As meta-regressions cannot be performed using the Revman 5.3 software, these were calculated using the 'metareg' program in STATA (version 15.1). If needed information for any of the above calculations was not reported in the publication, authors were contacted for further details. If data required for inclusion in the meta-analysis was not available, the study was included for descriptive review only. Due to the substantial diversity in reported outcomes, only outcomes reported at least three times at one time point were included for review.

## Results

### Study Selection

In total, 21663 titles were retrieved through database searches and over 500 titles were screened through secondary searches. After removing duplicates, 19788 titles remained. Screening of these titles resulted in the inclusion of 2212 abstracts, 1832 of which were excluded, leaving 380 full-texts to be reviewed. Seventeen manuscripts reporting on 15 studies were retained: twelve for inclusion in the meta-analysis and three for descriptive review only. Flow of studies and reasons for exclusion are included in Figure 1.

### Description of Studies

Characteristics of included studies are described in Table 1 and there was no indication of publication bias (Appendix C). Studies were conducted in the United Kingdom (n=5), United States (n=3), the Netherlands (n=2), Germany (n=2), Iran (n=1), Republic of Korea (n=1), and Australia (n=1). Eleven studies used a 2-group RCT design (including two pilot trials), two studies used a 2-group quasi-randomized experimental design, and one used a 3-group RCT design. The intervention groups were compared to usual care (n=6), attention control groups (n=6) (e.g., provided publicly available health information), or waitlist control (n=3).

### Participants

In total, 2064 participants were included in this review, with study sample sizes ranging from 40 (72) to 500 (73). Most studies (n = 12) included more women than men; two studies included only women (74, 75). Participants' primary diagnoses were cancer (n=7) (73, 75-80), diabetes type II (n=4) (72, 74, 81, 82), chronic heart disease (n=1) (83), chronic obstructive pulmonary disorder (n=1) (81), multiple sclerosis (MS) (n=1) (84), epilepsy (n=1) (85), and chronic kidney disease (n=1) (86) (non-exclusive categories as some studies focused on two illness groups). Mean reported age in the sample ranged from 35.0 to 70.8 years. Depressive symptomatology across study groups ranged from mild to severe, with the mean reported symptoms most often in the moderate range (35-38, 41-43, 87, 88).

### Interventions

Included interventions are described in Table 1. Six studies of the 15 studies evaluated the same or similar interventions, in different populations (73, 78-80, 85, 89). Time spent participating in interventions (intervention duration) ranged from 20 (82) to 2340 min (75) (n=14, mean=552.9, SD=662.9). The length of time over which interventions were delivered ranged from one session (82) to two 12-month programs (75, 77).

The primary format of the interventions was individual (n=11) (72, 73, 76, 78-85); however, three studies used a group format (74, 75, 86), and one included both group and individual sessions (77). In terms of mode of delivery, seven studies used a combination of face-to-face and telephone contact (most favoured face-to-face contact with telephone follow-up only if needed) (72, 73, 75, 78-80, 83), four were delivered entirely face-to-face (74, 77, 81, 86), three were online (76, 84, 85), and one was a video on a computer tablet (82).

In terms of level of guidance, most of the interventions were led by an interventionist (n=11) (72-75, 77-81, 83, 86), three were self-directed (two online programs and one a video) (82, 84, 85), and one intervention was guided self-directed (participants independently worked through the intervention with feedback on exercises) (76). The interventionists were all HCPs, other than one provided by a trained research assistant supervised by a psychologist (72). Four of the interventions were delivered by nurses supervised or supported by psychiatrists (73, 78-80), three were delivered solely by nurses (74, 81, 83), one by psychologists (75), and the remaining two interventions were delivered by interdisciplinary HCPs (76, 86).

The content of the interventions focused on a combination of structured problem-solving (n=12) (72, 73, 75-81, 83, 85), providing disease specific health information (n=13; it was an optional component in two of the 13) (72-75, 77-80, 82, 83, 85, 86), relaxation and stress management (n=7) (74, 75, 77, 82, 85, 86, 89), using CBT principles (e.g., challenging negative self-talk) (n=5) (74, 77, 81, 85, 89), care coordination (e.g., communicating the depressive symptoms to HCP team members) (n=4) (73, 78-80), and finding health services (n=2) (82, 83).

Eleven interventions were coded for a possible 13 depression SM skills (interventions that contained the same content were combined). The skills identified for each intervention are summarized in Appendix A. Across the sample, the mean number of skills was 6.2 (SD=2.4, range 2-11). The most frequently included skill was problem-solving (n=9), followed by decision-making (n=8), taking action (n=7), social support (n=7), and self-tailoring (n=7). Less frequently addressed skills were social support (n=1), resource utilization (n=2), and forming partnerships with HCPs (n=2).

## **Table 1**

*Descriptive Summary of Included Studies*

Author, Year, Aim(s) Country, Quality Assessment Score (QAS) (/17)	Demographics	Intervention and control conditions and assessments	Outcome(s) [Primary (P), Secondary (S), Unspecified (O)]
Barley et al., 2014 (83, 90) United Kingdom Pilot RCT (2 groups) QAS:12	To explore the acceptability and feasibility of procedures to inform a definitive RCT of a practice nurse-led personalised care intervention for CHD patients with at least probable depression and chest pain.	<b>Symptomatic chronic heart disease (with active chest pain)</b>  N=81 (T=41, C=40) Mean age: 65 (SD=11) % female = 35.8 Race/ethnicity: 83% white Mean HADS-D score: T=12 (SD=3), C=11 (SD=3)	<b>T:</b> Nine sessions (one face-to-face assessment + 15-min follow-up phone calls) with nurse focused on identifying problems contributing to depression, providing support resources, devising personal health plan, goal setting, and building self-efficacy.  <b>C:</b> Usual care.  <b>Format:</b> Individual.  <b>Mode of delivery:</b> Face-to-face and telephone.  <b>Interventionist:</b> Nurse.  <b>Intervention duration:</b> Mean 203 minutes (SD 100) with nurse (mean 78 SD19 for face-to-face assessment; mean 125 SD 91 in follow-up telephone calls).  <b>Intervention length:</b> 6-months.  <b>Level of guidance:</b> Guided  <b>Timing of measures:</b> 1-, 6-, and 12-months post baseline.
Boele et al., 2014 (76, 91) Netherlands RCT (3 groups) QAS: 10	To decrease depressive symptoms using low-intensity guided self-help based on problem-solving therapy delivered	<b>Glioma (CNS cancer)</b>  N=115 (T=45, C1=26, C2=44)	<b>T:</b> Guided self-help course based on problem-solving therapy including disease specific information. Five

online to increase accessibility and decrease barriers to accessing mental health care.	Mean age: T=43.6 (SD=11.7), C1=52.8 (SD=9.3), C2= 46.4 (SD=12.3)  % female: T=58.7, C1=54.9, C2=59.1  Most common diagnosis in C1: non-Hodgkin lymphoma (46.2%)  Mean CES-D score: T= 21.5 (SD=6.1), C1= 25.1 (SD=6.7), C2=24.1 (SD=6.6)	<b>modules and exercises. Online support and feedback on exercises provided by coach.</b>	<b>S: T1&gt;C2 for MCS (ES: 0.87)</b>
		<b>C1= Non-CNS cancer control group. Received intervention.</b>  <b>C2 = Glioma 12-week waitlist control group (WLC).</b>	<b>T1=C2 for PCS</b>

**Format: Individual.**

**Mode of delivery: Online**

**Interventionist: Psychologist, nurse, or psychology student.**

**Intervention duration: n/a**

**Intervention length: 5 weeks.**

**Level of guidance: Guided self-directed.**

**Timing of measures: 1.5-, 3-, 12-months post-baseline (last outcome measure not included for analysis as WLC group had completed intervention).**

Espahbodi et al., 2015 (86)  Iran  Quasi-experimental (randomized matched design)  QAS: 5	To investigate the impacts of education on psychological symptoms (anxiety and depression) in patient undergoing dialysis.	<b>Renal Failure (receiving dialysis)</b>  N=55 (T=27, C=28)  Mean age: T=49.1 (SD=14.5), C=52.3 (SD=15.6)  % female: T=52, C=50  Mean HADS-D: T=10.2 (SD=3.4), C=10.1 (SD=3.4)	<b>T: Psychoeducational intervention (3 sessions x 60 min) focused on disease-specific information (e.g., physiology, causes, treatments) as well as problem-solving, stress management, adaptive responses, and muscle relaxation.</b>  <b>C: Usual care.</b>  <b>Format: Group</b>	<b>P: T1=C for depression and anxiety</b>
---	--	---	--	---

		<b>Mode of delivery:</b> Face-to-face.		
		<b>Interventionist:</b> Unspecified. In collaboration with a nephrologist and psychiatrist.		
		<b>Intervention duration:</b> 180 minutes.		
		<b>Intervention length:</b> Approximately 5 days.		
		<b>Level of guidance:</b> Guided.		
		<b>Timing of measures:</b> 1.25-months post-baseline.		
Fischer et al., 2015 (89)  Germany  RCT (2 groups)  QAS: 8	To evaluate the feasibility and efficacy of a fully automated internet-based CBT program to reduce depressive symptoms in patients with multiple sclerosis (MS).	<p><b>Multiple sclerosis</b></p> <p>N=90 (T=45, C=45)</p> <p>Mean age: T=45.2 (SD=12.6), C=45.4 (SD=10.6)</p> <p>% female: T=76, C=80</p> <p>Mean BDI score: T=19.4 (SD=9.0), C=18.4 (SD=8.2)</p>	<p><b>T=</b> Ten online modules using simulated dialogue and tailored based on participant response. Content draws on: (1) Behavioral Activation, (2) Cognitive Modification, (3) Mindfulness and Acceptance, (4) Interpersonal Skills, (5) Relaxation, Physical Exercise and Lifestyle Modification, (6) Problem Solving, (7) Childhood Experiences and Early Schemas, (8) Positive Psychology Interventions, (9) Dreamwork and Emotion-Focused Interventions, and (10) Psychoeducation.</p> <p><b>C=</b> 2.25-month WLC</p> <p><b>Format:</b> Individual.</p> <p><b>Mode of delivery:</b> Online.</p> <p><b>Interventionist:</b> Self-directed.</p> <p><b>Intervention duration:</b> Self-directed. Mean use: 332</p>	<p><b>P:</b> T1=C for depression</p> <p><b>S:</b> T=C for fatigue</p>

minutes (range 50-905 minutes).

**Length of intervention:** 2.25 months.

**Level of guidance:** Self-directed.

**Timing of measures:** 2.25- and 8.25-months post-baseline (last outcome measure not included for analysis as WLC group had completed intervention).

Lamers et al., 2010a  
(81, 92)

Netherlands  
RCT (2 groups)  
QAS: 12

To evaluate the effectiveness of a nurse-administered minimal psychological intervention in reducing depressive symptoms in elderly primary care patients with type II diabetes or COPD with co-morbid non-severe depression.

### Type II diabetes, COPD

N=361(T=183, C=178)  
Mean age: T=70.8 (SD=6.5), C=70.6 (SD=6.8)  
% female: T=46.6, C=46.4  
Primary diagnosis:  
T: 49.7% diabetes, 50.3% COPD  
C: 52.8% diabetes, 47.2% COPD  
Mean BDI score:  
T=17.1 (SD=7.2)  
C=17.7 (SD=8.0)

**T**= Tailored intervention with variable number of sessions (2-10) based on principles of SM and CBT and includes 5 phases: exploring feelings and behaviours, mood monitoring, linking to behaviour, action planning, goal setting.

**C**= Usual care.

**Format:** Individual.

**Mode of delivery:** Face-to-face.

**Interventionist:** Nurse.

**Intervention duration:** Mean 240 minutes.

**Intervention length:** Tailored up to 3-months.

**Level of guidance:** Guided.

**Timing of measures:** Approximately 3.25-, 6-month, and 9-months post-

**P:** T1=C for depression

**T2=C for depression**

**S:** T1=C for MCS and PCS

**T2=C for MCS and PCS**

**COPD sub-group\***

T1=C for MCS

T2=C for MCS

**DMII sub-group\***

T1=C for MCS

T2=C for MCS

**baseline (assuming 3-month intervention period).**

Lamers et al. 2010b (93)  Note: Subgroup analysis of Lamers 2010a  Netherlands RCT (2 groups)	To evaluate the effectiveness of a nurse-administered minimal psychological intervention in reducing depressive symptoms in elderly primary care patients with COPD with co-morbid non-severe depression.	<b>COPD</b>  N=187 (T=96, C=91)  Mean age: T=70.5 (SD=6.3), C=71.5 (SD=7.1)  % female: T=41.8, C=38.5  Mean BDI score:  T=17.1 (SD=6.5), C=18.3 (SD=7.2)	See Lamers et al., 2010a	P: T1=C for depression*  T2=C for depression*
Lamers et al., 2011(94)  Note: Subgroup analysis of Lamers 2010a  Netherlands RCT (2 groups)	To evaluate whether a nurse-administered minimal psychological intervention based on CBT and SM principles improves disease-specific quality of life and glycemic control in patients with type II diabetes and co-morbid non-severe depression.	<b>Type II diabetes</b>  N=208 (T=105, C=103)  Mean age: T=70.7 (SD=6.6), C=69.7 (SD=6.6)  % female: T=51.4, C=50.4  Depression level: Not specified. Participants underwent Mini International Neuropsychiatric review. Those with minor depression, mild-to-moderate major depression or dysthymia were included.  Depression level: Not specified.	See Lamers et al., 2010a	P: T1=C for depression*  T2=C for depression*
Lee et al., 2014 (82)  Republic of Korea  Quasi-RCT – group allocation based on consent date (2 groups)  QAS: 12	To evaluate the effectiveness of a tablet PC-based single session psychoeducation intervention for cancer patients reporting significant levels of distress.	<b>Type II diabetes</b>  *per group data not available  N=111 (T=57, C=54)  Median age: 57.5 (range 34-71)  % female: 55.6  Mean HADS-D score:  T= 12.0 (SD=3.7), C=12.7 (SD=1.5)	<b>T= Twenty-minute psychoeducation video clip.</b> <b>Content consisted of distress education, cancer survivor interview, coping strategies and stress management, as well as psychological services.</b>  <b>C= Control movie clip of scenic images and relaxing music.</b>  <b>Format: Individual.</b>  <b>Mode of delivery: Video presented on computer tablet.</b>	P: T1>C for depression (ES: -1.13) and MCS (ES: 1.08)  T1=C for anxiety

		<b>Interventionist:</b> n/a	
		<b>Intervention duration:</b> 20-minutes.	
		<b>Length of intervention:</b> 20-minutes.	
		<b>Level of guidance:</b> Self-directed	
		<b>Timing of measures:</b> 1-day (post-intervention same day as baseline measures) and 2-4 weeks post-baseline.	
Moncrieff et al., 2016 (77)  United States  RCT (2 groups)  QAS: 9	To determine the effect of a multicomponent behavioural intervention on weight, glycemic control, renal function, and depressive symptoms in adults with DMII and depressive symptoms.	<p><b>Cancer patients receiving chemotherapy treatment</b></p> <p>N=36 (T=19, C=17)</p> <p>Mean age: T=54.8 (SD=8.3), C=54.8 (SD=6.3)</p> <p>% female: T=64.9, C=77.8</p> <p>Mean BDI-II score: T=19.3 (SD=7.1)</p> <p>C=21.2 (SD=7.1)</p>	<p><b>T:</b> Structured lifestyle intervention (17 sessions x 1.5-2 hours). Two individual sessions followed by two weekly, four bi-weekly, and nine monthly group sessions. Intervention components focused on diet and physical activity, including a weight loss, exercise, and caloric intake goals, combined with cognitive behavioural and social learning approaches to managing depression.</p> <p><b>C:</b> Usual care + brief educational booklet on diabetes management.</p> <p><b>Format:</b> Individual and group.</p> <p><b>Mode of delivery:</b> Face-to-face.</p> <p><b>Interventionist:</b> Therapists.</p> <p><b>Intervention duration:</b> 1530 to 2040 minutes.</p> <p><b>P:</b> T2&gt;C for depression (ES: -0.62)</p> <p><b>T2=C for glycemic control (HbA1c)</b></p>

		<b>Intervention length:</b> 12-months.	
		<b>Level of guidance:</b> Guided.	
		<b>Timing of measures:</b> 6- and 12-months post-baseline.	
Penckofer et al., 2012 (74) United States RCT (2 groups) QAS: 12	To examine the effects of a nurse-delivered psychoeducation intervention on depression, anxiety, and anger among women with type II diabetes.	<p><b>Type II diabetes</b></p> <p>N=74 (T=38, C=36)</p> <p>Mean age: T=58.4 (SD=8.8), C=54.0 (SD=8.4)</p> <p>% female: 100</p> <p>Mean CES-D score: T=27.7 (SD=9.3)</p> <p>C=28.9 (SD=9.5)</p>	<p><b>T= Sessions (8 weekly sessions + 2 booster sessions x 1 hour/session) focused on recognizing signs and symptoms of depression, relationship between mood, metabolic control, and self-care behaviours, the management of depression, anxiety, and anger using CBT. Includes elements from existing interventions such as CBT program for depression, progressive muscle relaxation CD, and system for management of anger including workbook and video.</b></p> <p><b>C= Usual care.</b></p> <p><b>Format: Group.</b></p> <p><b>Mode of delivery: Face-to-face.</b></p> <p><b>Interventionist: Nurse.</b></p> <p><b>Intervention duration: 600 minutes</b></p> <p><b>Intervention length:6-months</b></p> <p><b>Level of guidance: Guided.</b></p> <p><b>Timing of measures: 3- and 6-months post-baseline.</b></p>
			<b>P: T1&gt; C for depression (ES: -0.78)</b>
			<b>T1=C for trait anxiety</b>
			<b>T1=C for state anxiety</b>
			<b>T2&gt;C for depression (ES: -0.94) and trait anxiety (ES: -0.62)</b>
			<b>T2=C for state anxiety (ES: -0.74)</b>
			<b>S: T1=C for MCS</b>
			<b>T1=C for PCS and glycemic control (HbA1c)</b>
			<b>T2=C for glycemic control (HbA1c) and PCS</b>
			<b>T2&gt;C for MCS (ES: 0.60)</b>

<p>Rees et al., 2017(72) Australia Pilot RCT (2 groups) QAS: 12</p>	<p>To provide preliminary evidence for the impact of problem-solving therapy for diabetes in adults with diabetic retinopathy and diabetes distress.</p>	<p><b>Type II diabetes and diabetic retinopathy</b></p> <p>N=40 (T=21, C=19)</p> <p>Mean age: T=60.1 (SD=7.0), C=59.6 (SD=8.8)</p> <p>% female: T=33.3, C=31.6</p> <p>Mean PHQ-9 score: T=10.5 (SD=5.2)</p> <p>C=10.2 (SD=5.7)</p>	<p><b>T:</b> Provided publicly available information on diabetes + problem solving therapy for diabetes, which consisted of weekly sessions (8 x 45-60 min) in which participants identified problems related to diabetes and were guided through a problem-solving process (e.g., brainstorming solutions, obstacles to implementation, action plans). Participants were also asked to make plans to engage in enjoyable activities.</p>	<p><b>S:</b> T1=C for depression and glycemic control (HbA1c)</p>	<p><b>T2=C for depression and glycemic control (HbA1c)</b></p>
<p>Schroder et al., 2014 (85) Germany RCT (2 groups) QAS: 9</p>	<p>To evaluate the feasibility and efficacy of an online program for depression in individuals with epilepsy and comorbid</p>	<p><b>Epilepsy</b></p> <p>N=78 (T=38, C=40)</p> <p>Mean age: T=35.0 (SD=10.0), C= 40.0 (SD=11.9)</p>	<p><b>T:</b> Ten online modules (10-60 min each) comprised mostly of CBT elements (cognitive restructuring, behavioural</p>	<p><b>P:</b> T1=C for depression</p>	

	depressive symptoms.	% female: 75.6 Mean BDI score: T=22.2 (SD=10.4) C=19.4 (SD=9.8)	<b>activation) and mindfulness and acceptance exercises.</b>	
			<b>C: 9-week WLC</b>	
			<b>Format: Individual</b>	
			<b>Mode of delivery: Online.</b>	
			<b>Interventionist: Self-directed.</b>	
			<b>Intervention duration: 100-600 minutes.</b>	
			<b>Intervention length: 2.25 months.</b>	
			<b>Level of guidance: Self-directed.</b>	
			<b>Timing of measures: 2.25 months post-baseline.</b>	
Sharpe et al., 2004 (80)  United Kingdom (Scotland)  Non-randomized matched control group design (2 groups)  QAS: 12	To perform preliminary evaluation of the feasibility and efficacy of a nurse-led intervention with oncology outpatients.	<b>Cancer (outpatients with breast, gynaecological, bladder, prostate, testicular and colorectal)</b>  N=60 (T=30, C=30)  Mean age: T=58.0 (SD=10.6), C=56.0 (SD=10.5)  % female: T= 93.3, C=93.3  Mean HADS-D score:  T=10.4 (SD=3.6)	<b>T: The intervention consisted of up to 10 weekly problem-solving therapy sessions (30 min each) to help with a positive and systematic approach to tackling problems, education about depression, encouragement to speak with their general practitioner about anti-depressant medication, and coordination and monitoring of the participant's treatment. Participants could contact the nurse for further booster sessions.</b>  <b>C: Usual care.</b>	<b>P: T1&gt;C for depression (ES: -0.87)</b>  <b>T1&gt;C % of participants who no longer met criteria for major depressive disorder*</b>  <b>T2&gt;C for depression on HADS-D (ES: -0.58)</b>  <b>S: T1&gt;C for anxiety (ES: -1.25)</b>  <b>T2&gt;C for anxiety (ES: -0.88)</b>

**C=10.3  
(SD=4.0)**

**Interventionist: Nurse supervised by psychiatrist.**

**Intervention duration:** Nurse spent mean of 360 minutes with participants.

**Intervention length:** Ranged from 0.5-4 months (with 6 participants requesting booster sessions).

**Level of guidance:** Guided.

**Timing of measures:** 3- and 6-months post-baseline.

Sharpe et al., 2014  
(73)

### **(SMaRT Oncology-2)**

United Kingdom  
(Scotland)

RCT (2 groups)

QAS: 14

To compare the effectiveness of an integrated treatment programme for major depression in patients with cancer with usual care.

### **Cancer with prognosis of survival over 12-months.**

N=500 (T=253, C=247)

Mean age: T=56.6  
(SD=10.0), C= 56.1  
(SD=10.2)

% female: T = 90, C=90

Mean SLC-20 score:

T=2.10 (SD=0.62)

C=2.11 (SD=0.56)

**T:** Based on Strong et al. (2008). Primary care physician and oncologist informed of major depression disorder diagnosis + multicomponent treatment program integrated into cancer care in which participants form relationships with nurses who provide information about depression, deliver problem-solving therapy, and monitor progress (up to 10 sessions X 45 min and additional sessions available for those not meeting treatment targets).

**P:** T1> C for depression (ES: -0.87)

**T2>C for depression (ES: -1.03)**

**S:** T1>C for anxiety (ES: -0.61) and fatigue (ES: -0.41)

**T2>C for anxiety (ES: -0.71) and fatigue (ES: -0.60)**

**C:** Usual care + primary care physician and oncologist informed of major depression diagnosis + participant encouraged to consult their primary care physician to obtain treatment.

**Format: Individual.**

**Mode of delivery:** Primarily face-to-face, sometimes telephone.

**Interventionist:** Oncology nurses supervised by a psychiatrist.

**Intervention duration:** 405 min. Median number of sessions: 9 (range 0-10).

**Intervention length:** 4-months for initial sessions and further sessions for those who are not meeting treatment targets.

**Level of guidance:** Guided.

**Timing of measures:** 3-, 6-, 9-, and 12-months post-baseline.

Strong et al., 2008  
(79)

### **(SMaRT oncology 1)**

United Kingdom (Scotland)

RCT (2 groups)

QAS: 14

To assess the efficacy and cost of a nurse-delivered complex intervention designed to treat major depressive disorder in patients with cancer.

#### **Cancer**

N=200 (T=101, C=99)

Mean age: T=56.6 (SD=11.4), C= 56.6 (SD=12.3)

% female: T=69, C=72

Median SCL-20 score (IQR): T=2.35 (1.95-2.75), C=2.25 (1.95-2.75)

**T: Maximum of 10 session (45-min each) over 3-months followed monitoring of symptoms and optional 1-2 sessions in the next 3-months for those whose depression scores increased. The intervention included education about depression and treatment, problem-solving treatment, and communicating with the participant's primary care physician and oncologist about their depression diagnosis.**

**P: T1>C for depression\***

**T2>C for depression\***

**S: T1>C for anxiety and fatigue\***

**T2>C for anxiety and fatigue\***

**C: Usual care + informed primary care physician and oncologist of depression diagnosis and, if requested, provided advice regarding**

		<p><b>choice of antidepressant medication.</b></p>		
		<p><b>Format: Individual.</b></p>		
		<p><b>Mode of delivery: Primarily in-person, some by telephone if needed.</b></p>		
		<p><b>Interventionist: Oncology nurse supervised by a psychiatrist.</b></p>		
		<p><b>Intervention duration: Mean of 315 minutes based on mean of 7 sessions (range 2-10).</b></p>		
		<p><b>Intervention length: 6-months.</b></p>		
		<p><b>Level of guidance: Guided.</b></p>		
		<p><b>Timing of measures: 3-, 6-months post-baseline</b></p>		
Thorton et al., 2009 (75) United States RCT (2 groups) Secondary analysis QAS: 11	To test experimentally whether a psychological intervention reduces depression-related symptoms and markers of inflammation among cancer patients.	<p><b>Breast cancer (Stage II/III, surgically treated, and waiting for adjuvant therapies)</b></p> <p><b>N=45 (T=23, C=22)</b></p> <p><b>Mean age:</b> <b>T=50.0 (SD=8.6), C=50.0 (SD=11.6)</b></p> <p><b>% female: 100</b></p> <p><b>Mean CES-D Iowa short-form score not reported. All participants included in the</b></p>	<p><b>T: Group sessions (8-12 patients) for 1.5 hours for 18 weekly sessions followed by 8 monthly sessions. Topics included stress management, emotional distress, social adjustment, health behaviours (e.g., diet, exercise), and adherence to treatment.</b></p> <p><b>C: Usual care.</b></p> <p><b>Format: Group.</b></p> <p><b>Mode of delivery: Face-to-face (some telephone contact to catch up on information if sessions were missed).</b></p> <p><b>Interventionist: Psychologists.</b></p>	<p><b>P: T1&gt;C for depression*</b></p> <p><b>T2&gt; C for depression*</b></p> <p><b>S: T1&gt;C for fatigue*</b></p> <p><b>T2&gt;C for fatigue*</b></p>

**secondary analysis scored  $\geq 10$  as part of inclusion criteria.**

**Intervention duration: 2340 min.**

**Intervention length: 12-months.**

**Level of guidance: Guided.**

**Timing of measures: 4-, 8-, 12-months post-baseline.**

Walker et al., 2014  
(78)

### **(SMArt Oncology-3)**

United Kingdom  
(Scotland)

RCT (2 groups)

QAS: 13

To assess the efficacy of an integrated treatment program for major depressive disorder in patients with lung cancer compared with usual care.

### **Lung cancer**

N=142 (T=68, C=74)

Mean age: T=63.6 (SD=8.8), C= 63.9 (SD=8.7)

% female: T=64, C=65

Mean SCL-20 score:  
T=1.90 (SD 0.52), C=1.98 (0.58)

**T: Adapted from Sharpe et al. (2014). Maximum of 10 sessions (30-45 min) over 4 months followed by monitoring of symptoms and optional additional sessions for participants who did not meet treatment target. Nurses establish therapeutic relationship, provide information about depression, delivery problem-solving therapy and behavioural activation and monitor progress. Psychiatrists supervise treatment, advise primary care physicians, and provide direct consultation to participants not progressing.**

Outcomes averaged over the participants time in the trial (up to 32-weeks).

**P: T>C for depression\***

**S: T>C for anxiety\***

**T=C for fatigue\***

**C: Usual care + primary care physician and oncologist informed of the diagnosis of major depression and participant encouraged to see primary care physician to obtain treatment.**

**Format: Individual.**

**Mode of delivery: Primarily face-to-face, some telephone contact.**

**Interventionist: Nurse and psychiatrist.**

**Intervention duration: 240-360 minutes (median number of sessions 8 IQR 7-10).**

**Intervention length: 8-months.**

**Level of guidance: Guided.**

**Timing of measures: 4-, 8-, 12-, 16-, 20-, 24-, 28-, 32-weeks post-baseline.**

**Outcomes averaged over the participants time in the trial (up to 32-weeks).**

Notes: Only post-intervention primary and secondary outcomes of interest in this review reported across at least 3 studies within one time period (T1 and/or T2) included. T1- baseline to < 6 months post-baseline; T2  $\geq$  6 months post-baseline. T=treatment condition; C=control condition; T > C = treatment significantly superior to control; T < C = control superior to treatment; T = C = no significant differences between. ES= Effect size (Hedge's g calculated at 95% confidence level); Intervention duration= number of minutes spent participating in intervention based on reported participation or expected duration; Intervention length: Length of time over which intervention was delivered; \*Indicates that insufficient data available to calculate effect size so outcome is as reported by authors; sign of effect size based on negative orientation of scale (as intervention always compared with control – scales in which decreased scores indicate improvement are negative); Duration of the intervention based on reported mean or median adherence (in minutes) multiplied by the number of sessions, if needed, or, if not available, amount of time authors reported intervention would take (e.g., 4 sessions X 60 min= 240 min). If the range of individual sessions was provided (e.g., 15 to 30 minutes per session), the midpoint (e.g., 22.5) was multiplied by the number of sessions.; IQR=interquartile range; CHD = coronary heart disease, CNS = central nervous system, PST= problem-solving therapy; WLC = wait list control group; MS = multiple sclerosis; COPD= chronic obstructive pulmonary disorder; ER= emergency room; QoL=quality of life; CBT=cognitive behavioural therapy; BDI= Beck Depression Inventory (34); BDI-II= Beck Depression Inventory-II (36); CES-D= Centre for Epidemiological Studies-Depression (38); HADS-D= Hospital Anxiety and Depression Scale-Depression (42); PHQ-9= Patient Health Questionnaire (43); HRQoL=Health related Quality of Life and includes: PCS= physical health composite scale; MCS=mental health composite scale.

## **Methodological Quality**

Quality assessment scores are included in Table 1 and detailed scoring is available in Appendix D. The mean quality assessment score across the sample was 11.2 (SD 2.14) out of a possible 17 indicating that on average the studies were of moderate methodological quality. Scores ranged from 6 to 14 with four studies assessed as being of high methodological quality (72, 73, 78, 79). The least met criteria related to blinding.

## **Outcomes: Descriptive and Meta-analysis**

### ***Primary Outcome: Depression***

Eleven studies were included in the meta-analysis in the T1 period (see Figure 2). The pooled effect size of -0.47 [95% CI -0.73, -0.21] was significant with high heterogeneity  $I^2 = 76\%$  and favoured the interventions over the control conditions. The results remained significant after the Knapp-Hartung (KH) conversion [95% CI -0.74, -0.02]. Statistically significant effect sizes ranged from -0.78 (74) to -1.13 (82).

When examining potential sources of heterogeneity, three studies were found to have high pharmacological co-intervention that was significantly imbalanced across groups (73, 80, 83). When these were removed from the meta-analysis, the pooled effect size with 8 studies was of -0.41 [95% CI -0.61, -0.20] with  $I^2 = 32\%$ . Using both the DerSimonian–Laird and the more conservative KH approach and examining potential sources of heterogeneity, the findings of all analyses indicated a statistically significant moderate effect of interventions as compared to control conditions. The two studies not included in the meta-analysis measuring depression outcomes were in line with the findings from the meta-analysis (75, 79).

In the T2 time period, 7 studies were included in the meta-analysis (see Figure 3). The pooled effect size of -0.53 [95% CI -0.91, -0.15] was statistically significant with high heterogeneity,  $I^2 = 86\%$  favouring the interventions. The results remained significant after KH conversion [95% CI -95, -0.13]. Excluding the same three studies as in T1 (73, 80, 83) from the meta-analysis resulted in a pooled effect size, with 4 studies, of -0.53 [95% CI -0.84, -0.21] with moderate heterogeneity,  $I^2 = 50\%$ . The one study (78) not entered into the meta-analysis at T2 also favored the intervention over control group.

## **Secondary Outcomes**

A summary of results for secondary outcomes is presented in Table 2. Forest plots of meta-analysis results at the T1 and T2 periods for secondary outcomes is in Appendix E.

**Anxiety.** In the T1 period, 7 studies were entered in the meta-analysis (73, 74, 80, 82, 83, 86, 93). The pooled effect size was -0.42 [95% CI -0.73, -0.12] with heterogeneity of  $I^2 = 73\%$  in favour of the interventions. This finding remained significant after HK conversion [95% CI -0.82, -0.02]. Removing the same three studies as identified for depression (high pharmacological co-intervention) (73, 80, 83), the pooled effect size was significant, -0.29 [95% CI -0.53, -0.06], with no heterogeneity,  $I^2 = 0\%$ . One study (79) was not entered into the meta-analysis and favoured the intervention.

For the T2 time period, 4 studies were included in the meta-analysis (73, 74, 80, 83). The pooled effect size was -0.52 [95% CI -0.94, -0.10] with high heterogeneity,  $I^2 = 77\%$ . This was not significant after HK conversion. Removing the same three studies (73, 80, 83) did not decrease the heterogeneity. The one study (78) not entered into the meta-analysis reported a significant improvement in anxiety in the intervention group as compared to the control.

## **Health-related Quality of Life.**

**Mental Component Score (MCS) of Health-Related Quality of Life.** Five studies were included in the meta-analysis in the T1 period (74, 76, 82, 83, 93). The pooled effect size was statistically significant with moderate heterogeneity, 0.43 [0.09, 0.76] with  $I^2 = 60\%$ . However, it was not significant after HK conversion. Removing the results reported by Barley et al., 2014 (83) did not improve heterogeneity. For T2, the 3 studies were entered in the meta-analysis and did not result in significant pooled effect sizes (72, 74, 81).

## **Table 2**

*Effect Sizes for T1 and T2 for Secondary Outcomes*

Note: T1 baseline to <6-months; T2  $\geq$  6-months. HRQoL=Health-related Quality of Life.  $I^2$  = Higgins'  $I^2$  statistic. CI = confidence interval.

**Physical Component Score (PCS) of Health-Related Quality of Life.** Five studies were entered into the meta-analysis for the T1 period (74, 76, 81-83) and 3 studies for the T2 time period (74, 81, 83). The pooled effect sizes were not significant at either time point.

# Timepoints

	T1		T2		
Secondary Outcomes	# of studies	SMD (95% CI)	I <sup>2</sup> (%)	# of studies	SMD (95% CI)
Anxiety	7	-0.61 [-0.80, -0.43]	73	4	-0.52 [-0.94, -0.10]
Mental Component Score (HRQoL)	5	0.43 [0.09, 0.76]	60	3	-0.08 [-0.57, 0.41]
Physical Component Score (HRQoL)	5	0.01 [-0.18, 0.20]	0	3	0.03 [-0.18, 0.24]
Fatigue	3	-0.36 [-0.67, -0.06]	50	1	-0.60 [-0.78, -0.41]
Glycemic Control (HbA1c)	3	-0.08 [-0.57, 0.41]	49	4	-0.35 [-0.62, -0.07]

Fatigue. For the T1 period, three studies were included in the meta-analysis (73, 76, 89) and resulted in a significant pooled effect size of -0.36 [-0.67, -0.06] with moderate heterogeneity, I<sup>2</sup>=50%. The results were not significant if Sharpe, Walker (73) was removed from the analysis. For T2, only one study reported needed data for meta-analysis (73) and the results were statistically significant with an effect size of -0.60 [-0.78, -0.41] in favour of the intervention. Of the three studies not included in the meta-analysis, two reported in favour of the intervention at the T1 and T2 time periods (75, 79), and the remaining study reported no significant effect on this outcome (78).

Glycemic Control (HbA1c). Three studies were entered into the meta-analysis in the T1 period (72, 74, 94) and the results of the pooled effect size were not significant. At T2, 4 studies were included in the meta-analysis (72, 74, 77, 94) and the results were significant with an effect size of -0.35 [CI 95% -0.62, -0.07] and no heterogeneity, I<sup>2</sup>= 0%.

## Moderator Analyses

The results of the moderator analyses for the T1 time period are presented in Table 2. The three studies found to be outliers (73, 80, 83) were not included in these analyses. There was not enough data to perform meta-regression for the T2 period (4 studies total); however, 8 studies were included for the T1. Meta-regressions were performed for the following 5 moderators as there were 4 studies in each sub-group: duration of the intervention (<300 min or  $\geq$  300 min), behavioural activation (yes/no), health habits (yes/no), self-tailoring (yes/no), and number of SM skills included in the intervention (1-6 or 7-13). None were found to be significant. Additional meta-regressions were run for the following 9 moderators including a minimum of 3 studies per sub-group: baseline depression level of the study sample (mild to moderate/moderately severe to severe), level of guidance (guided/self-directed), intervention provider (professional or self-directed), length of the intervention (< 3 months/  $\geq$  3 months), decision-making (yes/no), taking action (yes/no), cognitive restructuring (yes/no), self-monitoring (yes/no), and relaxation (yes/no). The results were significant for the two SM skills of decision-making ( $p=0.020$ ) and taking action ( $p=0.017$ ).

## Table 3

*Moderator Analyses Outcomes T1*

Variables	# of studies	Pooled ES	L95	U95	P-value	$I^2$	Meta-regression p-value
<b>Overall</b>	8	-0.41	-0.61	-0.20	<0.001	32%	
<b>Disease</b>							
Cancer	1	-0.45	-1.05	0.15			
Other	7	-0.41	-0.65	-0.18	0.001	41%	
<b>Baseline depression level</b>							0.926
Mild to moderate	5	-0.42	-0.72	-0.11	0.007	44%	
Moderate severe to severe	3	-0.43	-0.75	-0.11	0.009	26%	
<b>Level of guidance</b>							0.840
Guided	5	-0.37	-0.62	-0.13	0.002	26%	
Self-directed	3	-0.49	-0.96	-0.02	0.042	56%	
<b>Mode of delivery</b>							0.840
Face to face	5	-0.37	-0.62	-0.13	0.002	26%	
Not face to face	3	-0.49	-0.96	-0.02	0.042	56%	
<b>Provider</b>							0.840
Professional	5	-0.38	-0.63	-0.14	0.002	28%	
Self-directed	3	-0.5	-0.98	-0.02	0.042	58%	
<b>Format</b>							
Individual	6	-0.33	-0.55	-0.11	0.004	25%	
Group	2	-0.65	-1.01	-0.28	0.001	0%	
<b>Duration of Intervention</b>							1.000
<300 min	4	-0.47	-0.85	-0.09	0.016	58%	
≥ 300	4	-0.41	-0.66	-0.16	0.002	0%	
<b>Control Group</b>							
Active	2	-0.70	-1.52	0.11	0.09	64%	
Not active	6	-0.33	-0.51	-0.15	<0.001	10%	
<b>Methodological Quality</b>							
Low	1	-0.49	-1.03	0.04	0.072		
Moderate	7	-0.41	-0.64	-0.17	0.001	40%	

<b>Length of Intervention</b>							0.858
< 3 months	5	-0.43	-0.70	-0.17	0.001	15%	
≥ 3 months	3	-0.41	-0.81	-0.02	0.042	60%	
<b>Depression Self-Management Skills</b>							
<b>Decision-making</b>							0.016*
No	3	-0.75	-1.08	-0.42	<0.001	0%	
Yes	5	-0.23	-0.41	-0.05	0.011	0%	
<b>Problem-solving</b>							
No	2	-0.90	-1.31	-0.48	<0.001	0%	
Yes	6	-0.26	-0.43	-0.09	0.003	0%	
<b>Resource Utilization</b>							
No	7	-0.31	-0.47	-0.15	<0.001	0%	
Yes	1	-1.13	-1.85	-0.41	0.002		
<b>Partnerships with HCPs</b>							
No	7	-0.49	-0.70	-0.28	<0.001	4%	
Yes	1	-0.16	-0.4	0.08	0.197		
<b>Taking Action</b>							0.020*
No	3	-0.75	-1.08	-0.42	<0.001	0%	
Yes	5	-0.23	-0.41	-0.05	0.011	0%	
<b>Behavioural Activation</b>							1.000
No	4	-0.47	-0.85	-0.09	0.016	58%	
Yes	4	-0.41	-0.66	-0.16	0.002	0%	
<b>Cognitive Restructuring</b>							0.297
No	3	-0.61	-1.06	-0.16	0.008	34%	
Yes	5	-0.32	-0.53	-0.11	0.003	21%	
<b>Self-monitoring</b>							0.694
No	5	-0.45	-0.71	-0.19	0.001	12%	
Yes	3	-0.38	-0.78	0.02	0.065	57%	
<b>Health Habits</b>							0.283
No	4	-0.25	-0.45	-0.05	0.014	0%	
Yes	4	-0.56	-0.93	-0.19	0.003	49%	
<b>Communicating about</b>							

## Depression

No	7	-0.34	-0.53	-0.14	0.001	17%
Yes	1	-0.78	-1.29	-0.27	0.003	

## Social Support

No	3	-0.23	-0.43	-0.02	0.036	0%
Yes	5	-0.53	-0.82	-0.23	<0.001	33%

## Relaxation

No	3	-0.21	-0.42	0.00	0.053	0%
Yes	5	-0.53	-0.82	-0.25	<0.001	32%

## Self-tailoring

No	4	-0.47	-0.80	-0.14	0.005	34%
Yes	4	-0.37	-0.67	-0.07	0.015	40%

## Number of Skills

1 - 6	4	-0.56	-0.88	-0.24	0.001	6%
7-13	4	-0.32	-0.57	-0.07	0.013	37%

Random effect model was used to compute the pooled effect size

\*p<0.05 indicating statistical significance

## Discussion

To our knowledge, this is the first systematic review to examine the effect of SM interventions on reducing depressive symptoms among people with chronic physical disease(s) and co-occurring depression. The results were drawn from the findings of 15 studies. Meta-analysis was conducted for two time periods for the primary outcome of depression as well as the secondary outcomes of anxiety, health-related quality of life (mental component and physical component), fatigue, and glycemic control. Analyses of potential moderators of intervention effect on the primary outcome were performed to identify active elements. Overall, the findings support: a) an effect of interventions on improving depression and anxiety as well as glycemic control at  $\geq$  6-months post-baseline, b) intervention duration and intervention length do not seem to impact effect, c) some moderators merit further attention in future studies, including level of guidance and type of SM skills included.

## Effect on Participant Outcomes

The results of the review indicate a moderate effect of SM interventions on depression and a small effect on anxiety. These results are consistent with the broader literature on SM for individuals with depression or chronic physical diseases. A systematic review by Houle et al. (2013) found that SM interventions reduced depressive symptomatology in the general adult population and improved functioning, self-efficacy, and self-management behaviours (59). Findings related to relapse of depression were mixed. The results of the present review could not shed further light on this issue, as only three studies reported intervention and control group data at 12 or more months (77, 83, 95). Another recent systematic review assessing the effect of face-to-face SM interventions for adults with a chronic diseases (not necessarily with co-morbid depression) found that efficacious interventions were more likely to include psychological coping or stress management strategies (27).

Results of the present review can also be compared to those of a review of psychotherapy for adults with depression (with or without chronic co-morbid chronic conditions) that found the interventions to have a larger but still moderate effect size ( $d=0.68$ ) in improving depressive symptoms (96). Reviews of the effect of psychotherapy on co-morbid depression in adults with chronic physical diseases report between small and large effect sizes (97). Due to the relatively small number of studies, strong comparisons or conclusions cannot be drawn; however, results suggest that depression SM interventions for this population may have a similarly beneficial effect while generally being more cost-effective.

## Moderator Analyses

The analyses of moderators found no significant difference in intervention effect on depression based on intervention length or duration. These findings have important implications for the integration of such interventions into resource constrained clinical environments. Seeking evidence-based cost- and time-effective interventions is imperative for the sustainability of providing interventions in clinical practice (27). As feasibility is a priority, further investigation of these intervention characteristics is warranted.

Self-directed interventions (no contact with an HCP or coach) did not have significantly lower effect sizes than guided ones. However, this must be interpreted with much caution as the sample size was very small. A number of reviews that support the efficacy of minimally guided and self-directed interventions (98-101). A review of self-directed psychological interventions found a small significant effect of interventions ( $d=0.23$  at post-test,  $d=0.28$  from 4- to 12-months) on depression. Only one trial to our knowledge has directly compared the effects of a guided (coached) and self-directed intervention (102). This trial was excluded from our meta-analysis because of the active control. The results indicated an overall significant benefit of coaching on depressive symptoms at 3 months; among those who were not receiving psychological treatment at study entry, the benefit was extended to 6 months. The increased effect is likely explained by the greater adherence to the self-care tools in the coached (guided) group. As indicated in the NICE guidelines, such interventions may also be valuable in a stepped care approach to depression treatment, wherein those who do not respond to initial low intensity treatment are 'stepped up' to more intensive treatment (e.g., more guidance or HCP contact, pharmacotherapy) (22, 99).

The results indicated that not all SM skills may be equally beneficial in improving depressive symptoms. Of the 13 SM skills examined, two of them, decision-making and taking action, were potentially significant moderators of the primary outcome of depression. Of the skills examined, six, drawn from the work of Lorig & Holman (2003), are considered "core" SM skills that are applicable across chronic diseases. The remaining seven skills were drawn from the literature specifically on the SM of depression. The findings of this study parallel those of a previous review of non-pharmacological depression interventions for caregivers, which found that problem-solving, decision-making, and taking action were significant moderators of depression (64). It is notable that neither review identified depression specific skills as significant moderators. Interestingly, a review of SM interventions in a different population, adults with low income or low health literacy, also found that problem-solving and taking action were more often included in effective interventions (63). Due to limited data it was not possible to examine problem-solving in this review. Together, the findings of these reviews suggest that developing core SM skills to foster behaviour change might be more important than disease-specific SM skills.

## Methodological Quality

The majority of studies were of moderate methodological quality and none met all of the criteria. Due to insufficient sample size, it was not possible to examine the heterogeneity among studies of different methodological quality. Adherence rates were reported in nine of 15 studies, similar to a previous review of self-care interventions for anxiety or depression that found 55% of studies reported adherence measures (103). A number of studies described the amount of time participants engaged in the intervention; however, no study indicated a minimal therapeutic dose or exposure to the intervention. More detailed standardized measures of adherence including activity or module completion, time spent, and active engagement have been proposed to address this issue (104). The pre-established criteria, based on Cochrane Risk of Bias tool, were difficult to apply to self-directed interventions. For example, intervention fidelity becomes essentially synonymous with adherence in the case of self-directed interventions; blinding of participants to group allocation may be of greater importance as they are in essence the interventionists and frequently self-report their own outcomes.

If attrition was 20% or less across the sample, the criterion was assessed as being met (65, 105). However, in six of the studies, attrition rates were notably higher in the intervention group as compared to the control (72, 74, 77, 81, 83, 85) and no studies reported greater attrition in the control group. This raises concern regarding the potential impact of attritional bias on study outcomes (106). Though four of these studies used intention-to-treat analyses, this may not entirely mitigate the impacts of this missing data (107). Reporting the baseline characteristics of participants who were and were not included in analyses is recommended to help address this (107). Further, previous work has addressed predictors of attrition of participants with depression from pharmacological trials, but this has not been thoroughly addressed in psychosocial trials (108, 109).

## Reported Outcomes

There was substantial variety in the outcomes reported across studies and measurement instruments used. Of the 38 outcomes measured across studies, only five were reported at least three times at one time point. Further, six instruments were used to measure the primary outcome of depression. These instruments were also used to establish the presence of at least mild symptoms of depression across the sample, a criterion for inclusion in this review. This is notable as a recent co-calibration study examining the variations in the five commonly used depression self-report instruments found that the cut-off scores across scales were not equivalent (110). The impact of this on the primary outcome could have resulted in an under-or over-estimation of intervention effect.

## Strengths And Limitations

The study methods were guided by the Cochrane Handbook and the PRISMA statement, and the protocol was registered with PROSPERO (32, 33). The methods were outlined in detail and are reproducible. Given some terminological ambiguity in the literature regarding what constitutes an SM intervention, another strength of this review was the search terms applied were very inclusive. Interventions that were not self-described as SM were included in the review based on the meeting the predetermined definition based on current SM literature. This is in line with recommendations by Lorig and Holman (2003). However, due to the variations in definitions of SM, it is possible that other teams would have identified different interventions for inclusion. Further, the results should be interpreted with caution as the sample size was small with substantial heterogeneity, though this was found to be largely attributable to the confounding impact of pharmacotherapy. The limited number of studies prevented further examination of sources of heterogeneity and analyses of moderators was also conducted with a very small sample. There was only sufficient data to examine outcomes up to 6-months; longer-term outcome data is needed. Further, the

majority of the included studies were focused on those with cancer or diabetes. Though the findings offer potential future avenues for exploration, further evidence is required to investigate longer-term outcomes, sources of heterogeneity, and possible differences in chronic physical disease populations.

## Conclusion

This is the first systematic review to examine the effect of SM interventions on depression in adults with co-occurring chronic physical diseases. The findings indicate the interventions reduced depression with a moderate effect size and anxiety with a small effect size. Impact of the interventions on other psychosocial and physical health outcomes was mixed. Recommendations include further evaluation of the impact on the amount of guidance, length, and duration of interventions, as self-directed and shorter, less resource intensive interventions may be effective. Including self-management skills of decision-making and taking-action in future interventions is also recommended.

## Declarations

### Declarations

**Ethics approval and consent to participate:** Not applicable.

**Consent for publication:** Not applicable.

**Availability of data and materials:** The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Competing interests:** The authors declare that they have no competing interests.

**Funding:** This work was supported by the Fonds de recherche santé Québec (FRQS), the Réseau de recherche en interventions en sciences infirmières (RRISIQ), Dr. Lambert's Tier 2 Canada Research Chair and the McGill Nursing Collaborative for Education and Innovation in Patient and Family Centered Care.

#### Authors' contributions:

LOB: Conceptualized and designed the work, collected, analyzed, and interpreted data, and drafted the manuscript.

SL: Conceptualized and designed the work, contributed to data collection and assisted with interpreting data, and substantially revised the manuscript.

NF: Assisted in designing the work, interpreting the data, and substantially revised the manuscript.

CC: Conducted data collection and substantially revised the manuscript.

JS: Conducted data collection and substantially revised the manuscript.

JC: Contributed to conceptualizing and designing the work and substantially revised the manuscript.

EM: Contributed to data analysis and interpretation and substantially revised the manuscript.

JK: Contributed to data collection and substantially revised the manuscript.

KK: Contributed to data collection.

ES: Conducted some data analysis, assisted with data interpretation, and substantially revised manuscript.

CG: Contributed to data interpretation and substantially revised manuscript.

All authors read and approved the final manuscript.

**Acknowledgements:** Not applicable.

## References

1. World Health Organization. Depression Fact Sheet: World Health Organization; 2018 [Available from: <http://www.who.int/mediacentre/factsheets/fs369/en/>.]
2. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annual review of public health. 2013;34:119-38.
3. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. Scientific Reports. 2018;8(1):2861.
4. World Health Organization. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2016. Geneva: World Health Organization; 2018.
5. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet (London, England). 2007;370(9590):851-8.

6. Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. *Dialogues in clinical neuroscience*. 2011;13(1):7-23.
7. Li H, Ge S, Greene B, Dunbar-Jacob J. Depression in the context of chronic diseases in the United States and China. *Int J Nurs Sci*. 2018;6(1):117-22.
8. World Health Organization & Public Health Agency of Canada. Preventing chronic diseases: a vital investment: World Health Organization; 2005.
9. World Health Organization. Noncommunicable diseases 2018 [Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>].
10. Gonzalez JS, Peyrot M, McCarl LA, Collins EM, Serpa L, Mimiaga MJ, et al. Depression and diabetes treatment nonadherence: a meta-analysis. *Diabetes Care*. 2008;31(12):2398-403.
11. Kravitz RL, Ford DE. Introduction: chronic medical conditions and depression—the view from primary care. *Am J Med*. 2008;121(11 Suppl 2):S1-S7.
12. National Institute for Health and Clinical Excellence. Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society; 2010.
13. Cuijpers P, Smit F. [Subclinical depression: a clinically relevant condition?]. *Tijdschr Psychiatr*. 2008;50(8):519-28.
14. Tuithof M, Ten Have M, van Dorsselaer S, Kleinjan M, Beekman A, de Graaf R. Course of subthreshold depression into a depressive disorder and its risk factors. *Journal of affective disorders*. 2018;241:206-15.
15. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. *The Medical journal of Australia*. 2009;190(S7):S54-60.
16. Craven MA, Bland R. Depression in Primary Care: Current and Future Challenges. *The Canadian Journal of Psychiatry*. 2013;58(8):442-8.
17. Mojtabai R, Olfson M, Sampson NA, Jin R, Druss B, Wang PS, et al. Barriers to mental health treatment: results from the National Comorbidity Survey Replication. *Psychological medicine*. 2011;41(8):1751-61.
18. Renn BN, Hoeft TJ, Lee HS, Bauer AM, Areán PA. Preference for in-person psychotherapy versus digital psychotherapy options for depression: survey of adults in the U.S. *npj Digital Medicine*. 2019;2(1):6.
19. Fournier L, Roberge P, Brouillet H. Faire face à la dépression au Québec. Protocole de soins à l'intention des intervenants de première ligne Centre de recherche du CHUM: Montréal. 2012.
20. Patten SB, Kennedy SH, Lam RW, O'Donovan C, Filteau MJ, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. *J Affect Disord*. 2009;117 Suppl 1:S5-14.
21. Health Quality Ontario. Major Depression: Care for Adults and Adolescents. Toronto, ON: Health Quality Ontario; 2016.
22. National Institute for Health Care Excellence. Depression in adults with a chronic physical health problem: recognition and management In: Guideline C, editor. 2009.
23. Institute of Medicine Committee on the Crossing the Quality Chasm: Next Steps Toward a New Health Care System. In: Adams K, Greiner AC, Corrigan JM, editors. The 1st Annual Crossing the Quality Chasm Summit: A Focus on Communities. Washington (DC): National Academies Press (US); 2004.
24. McGowan P, Fredericks, S., & Beatty, G. Strategies to Support Self-Management in Chronic Conditions: Collaboration with Clients. . Toronto, ON: Registered Nurses Association of Ontario (RNAO); 2010.
25. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. 2003;26(1):1-7.
26. Bodenheimer T, Wagner EH, Grumbach K. Improving Primary Care for Patients With Chronic Illness. *JAMA*. 2002;288(14):1775-9.
27. Dineen-Griffin S, Garcia-Cardenas V, Williams K, Benrimoj SI. Helping patients help themselves: A systematic review of self-management support strategies in primary health care practice. *PloS one*. 2019;14(8):e0220116.
28. Bodenheimer T, Lorig K, Holman H, Grumbach K. Patient self-management of chronic disease in primary care. *Jama*. 2002;288(19):2469-75.
29. Bilsker D, Goldner EM, Anderson E. Supported self-management: a simple, effective way to improve depression care. *Canadian journal of psychiatry Revue canadienne de psychiatrie*. 2012;57(4):203-9.
30. Bower P, Richards D, Lovell K. The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review. *The British journal of general practice : the journal of the Royal College of General Practitioners*. 2001;51(471):838-45.
31. Jones MC, MacGillivray S, Kroll T, Zohoor AR, Connaghan J. A thematic analysis of the conceptualisation of self-care, self-management and self-management support in the long-term conditions management literature. *Journal of Nursing and Healthcare of Chronic Illness*. 2011;3(3):174-85.
32. Higgins JPT, Green SE. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 Higgins JPTG, S. (Eds). editor: The Cochrane Collaboration; 2011.
33. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine*. 2009;151(4):264-9, w64.
34. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. *Clinical Psychology Review*. 1988;8(1):77-100.
35. Beck AT, Rush, A. J., Shaw B. F., & Emery, G. Cognitive therapy of depression. New York, NY: Guilford Press; 1979.
36. Beck AT, Steer, R.A., & Brown, G.K. Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation; 1996.
37. Vilagut G, Forero CG, Barbaglia G, Alonso J. Screening for Depression in the General Population with the Center for Epidemiologic Studies Depression (CES-D): A Systematic Review with Meta-Analysis. *PloS one*. 2016;11(5):e0155431.

38. Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. *Applied Psychological Measurement*. 1977;1(3):385-401.
39. Kohout FJ, Berkman LF, Evans DA, Cornoni-Huntley J. Two Shorter Forms of the CES-D Depression Symptoms Index. *Journal of Aging and Health*. 1993;5(2):179-93.
40. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). *Am J Prev Med*. 1994;10(2):77-84.
41. Hamilton M. A rating scale for depression. *Journal of neurology, neurosurgery, and psychiatry*. 1960;23:56-62.
42. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta psychiatica Scandinavica*. 1983;67(6):361-70.
43. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *Journal of general internal medicine*. 2001;16(9):606-13.
44. Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. *J Psychiatr Res*. 1982;17(1):37-49.
45. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (3rd ed.). Washington, DC: Author; 1980.
46. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (3rd ed., revised.). Washington, DC: Author; 1987.
47. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed.). . Washington, DC: Author; 1994.
48. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4th ed., text revision.). Washington, DC: Author; 2000.
49. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author; 2013.
50. World Health Organization (WHO). International Classification of Disease (ICD-9). . Geneva: World Health Organization; 1977.
51. World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines.. Geneva: World Health Organization; 1992.
52. Public Health Agency of Canada. Chronic Diseases. Government of Canada; 2013.
53. Drug and Therapeutics Bulletin. Management of seasonal affective disorder. *BMJ*. 2010;340:c2135.
54. Kurlansik SL, Ibay AD. Seasonal affective disorder. *American family physician*. 2012;86(11):1037-41.
55. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. *Lancet (London, England)*. 2002;359(9302):241-7.
56. O'Hara MW, Wisner KL. Perinatal mental illness: definition, description and aetiology. *Best practice & research Clinical obstetrics & gynaecology*. 2014;28(1):3-12.
57. Partners). BCPfMHaAIB. Depression Toolkit: Information and Resources for Effective Self-Management of Depression. 2003 [Available from: [http://www.gpscbc.ca/sites/default/files/uploads/AMH\\_212.0\\_Depression\\_Toolkit\\_PR.pdf](http://www.gpscbc.ca/sites/default/files/uploads/AMH_212.0_Depression_Toolkit_PR.pdf)].
58. Bilsker D, Paterson R. Antidepressant skills workbook. . Vancouver, BC: Simon Fraser University; 2005.
59. Houle J, Gascon-Depatie M, Bélanger-Dumontier G, Cardinal C. Depression self-management support: a systematic review. *Patient Educ Couns*. 2013;91(3):271-9.
60. Regan T, Lambert SD, Kelly B. Uptake and attrition in couple-based interventions for cancer: perspectives from the literature. *Psycho-Oncology*. 2013;22(12):2639-47.
61. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015 Guideline Statement. *Journal of clinical epidemiology*. 2016;75:40-6.
62. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. *Journal of the Medical Library Association : JMLA*. 2016;104(3):240-3.
63. Schaffler J, Leung K, Tremblay S, Merdsoy L, Belzile E, Lambrou A, et al. The Effectiveness of Self-Management Interventions for Individuals with Low Health Literacy and/or Low Income: A Descriptive Systematic Review. *Journal of general internal medicine*. 2018;33(4):510-23.
64. Lambert S, Ould Brahim L, McCusker J, Coumoundouros C, Audet L, Yaffe M, et al. Non-pharmacological interventions for caregivers with depression and caregivers of care recipients with co-morbid depression: A systematic review and meta-analysis. Manuscript submitted for publication. 2020.
65. Higgins JPT SJ, Savović J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S, . A revised tool for assessing risk of bias in randomized trials. 2016. In: Cochrane Database of Systematic Reviews [Internet]. [Suppl 1]. Available from: [dx.doi.org/10.1002/14651858.CD201601](https://doi.org/10.1002/14651858.CD201601).
66. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando: Academic Press; 1985.
67. Cooper HM, Hedges LV, Valentine JC. Handbook of research synthesis and meta-analysis. New York: Russell Sage Foundation; 2019. Available from: <https://muse.jhu.edu/book/65827/>
- <http://www.jstor.org/stable/10.7758/9781610448864>
- <http://www.vlebooks.com/vleweb/product/openreader?id=none&isbn=9781610448864>.
68. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd Edition ed. New York, NY: Lawrence Erlbaum Associates; 1988.
69. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-effects meta-analysis of inconsistent effects: a time for change. *Annals of internal medicine*. 2014;160(4):267-70.
70. Kraemer HC, Wilson GT, Fairburn CG, Agras WS. Mediators and Moderators of Treatment Effects in Randomized Clinical Trials. *Archives of General Psychiatry*. 2002;59(10):877-83.

71. Fu R, Gartlehner G, Grant M, Shamsiyan T, Sedrakyan A, Wilt TJ, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program. *Journal of clinical epidemiology*. 2011;64(11):1187-97.
72. Rees G, O'Hare F, Saeed M, Sudholz B, Sturrock BA, Xie J, et al. Problem-solving therapy for adults with diabetic retinopathy and diabetes-specific distress: a pilot randomized controlled trial. *BMJ Open Diabetes Res Care*. 2017;5(1):e000307.
73. Sharpe M, Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, et al. Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial. *The Lancet*. 2014;384(9948):1099-108.
74. Penckofer SM, Ferrans C, Mumby P, Byrn M, Emanuele MA, Harrison PR, et al. A psychoeducational intervention (SWEEP) for depressed women with diabetes. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. 2012;44(2):192-206.
75. Thornton LM, Andersen BL, Schuler TA, Carson WE, 3rd. A psychological intervention reduces inflammatory markers by alleviating depressive symptoms: secondary analysis of a randomized controlled trial. *Psychosom Med*. 2009;71(7):715-24.
76. Boele FW, Klein M, Verdonck-de Leeuw IM, Cuijpers P, Heimans JJ, Snijders TJ, et al. Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial. *J Neurooncol*. 2018;137(1):191-203.
77. Moncrieff AE, Llabre MM, McCalla JR, Gutt M, Mendez AJ, Gellman MD, et al. Effects of a Multicomponent Life-Style Intervention on Weight, Glycemic Control, Depressive Symptoms, and Renal Function in Low-Income, Minority Patients With Type 2 Diabetes: Results of the Community Approach to Lifestyle Modification for Diabetes Randomized Controlled Trial. *Psychosom Med*. 2016;78(7):851-60.
78. Walker J, Hansen CH, Martin P, Symeonides S, Gourley C, Wall L, et al. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. *Lancet Oncol*. 2014;15(10):1168-76.
79. Strong V, Waters R, Hibberd C, Murray G, Wall L, Walker J, et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. *Lancet (London, England)*. 2008;372(9632):40-8.
80. Sharpe M, Strong V, Allen K, Rush R, Maguire P, House A, et al. Management of major depression in outpatients attending a cancer centre: a preliminary evaluation of a multicomponent cancer nurse-delivered intervention. *Br J Cancer*. 2004;90(2):310-3.
81. Lamers F, Jonkers CC, Bosma H, Kempen GI, Meijer JA, Penninx BW, et al. A minimal psychological intervention in chronically ill elderly patients with depression: a randomized trial. *Psychotherapy and psychosomatics*. 2010;79(4):217-26.
82. Lee JY, Park HY, Jung D, Moon M, Keam B, Hahm BJ. Effect of brief psychoeducation using a tablet PC on distress and quality of life in cancer patients undergoing chemotherapy: a pilot study. *Psycho-oncology*. 2014;23(8):928-35.
83. Barley EA, Walters P, Haddad M, Phillips R, Achilla E, McCrone P, et al. The UPBEAT nurse-delivered personalized care intervention for people with coronary heart disease who report current chest pain and depression: a randomised controlled pilot study. *PloS one*. 2014;9(6):e98704.
84. Fischer A, Schröder J, Vettorazzi E, Wolf OT, Pöltgen J, Lau S, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. *Lancet Psychiatry*. 2015;2(3):217-23.
85. Schroder J, Bruckner K, Fischer A, Lindenau M, Kother U, Vettorazzi E, et al. Efficacy of a psychological online intervention for depression in people with epilepsy: a randomized controlled trial. *Epilepsia*. 2014;55(12):2069-76.
86. Espahbodi F, Hosseini H, Mirzade MM, Shafaat AB. Effect of Psycho Education on Depression and Anxiety Symptoms in Patients on Hemodialysis. *Iran J Psychiatry Behav Sci*. 2015;9(1):e227-e.
87. Derogatis LR. The SCL-90 Manual I: Scoring, administration and procedures for the SCL-90. Baltimore, MD: Clinical psychometric research. 1977.
88. O'Connor M, Butcher I, Hansen CH, Kleiboer A, Murray G, Sharma N, et al. Measuring improvement in depression in cancer patients: a 50% drop on the self-rated SCL-20 compared with a diagnostic interview. *General hospital psychiatry*. 2010;32(3):334-6.
89. Fischer A, Schröder J, Vettorazzi E, Wolf OT, Pöltgen J, Lau S, et al. An online programme to reduce depression in patients with multiple sclerosis: a randomised controlled trial. *The Lancet Psychiatry*. 2015;2(3):217-23.
90. Tylee A, Barley EA, Walters P, Achilla E, Borschmann R, Leese M, et al. Programme Grants for Applied Research. UPBEAT-UK: a programme of research into the relationship between coronary heart disease and depression in primary care patients. Southampton (UK): NIHR Journals Library; 2016.
91. Boele FW, Verdonck-de Leeuw IM, Cuijpers P, Reijneveld JC, Heimans JJ, Klein M. Internet-based guided self-help for glioma patients with depressive symptoms: design of a randomized controlled trial. *BMC neurology*. 2014;14:81.
92. Lamers F, Jonkers CC, Bosma H, Diederiks JP, van Eijk JT. Effectiveness and cost-effectiveness of a minimal psychological intervention to reduce non-severe depression in chronically ill elderly patients: the design of a randomised controlled trial [ISRCTN92331982]. *BMC public health*. 2006;6:161.
93. Lamers F, Jonkers CC, Bosma H, Chavannes NH, Knottnerus JA, van Eijk JT. Improving quality of life in depressed COPD patients: effectiveness of a minimal psychological intervention. *Copd*. 2010;7(5):315-22.
94. Lamers F, Jonkers CC, Bosma H, Knottnerus JA, van Eijk JT. Treating depression in diabetes patients: does a nurse-administered minimal psychological intervention affect diabetes-specific quality of life and glycaemic control? A randomized controlled trial. *Journal of advanced nursing*. 2011;67(4):788-99.
95. Sharpe M, Strong V, Allen K, Rush R, Maguire P, House A, et al. Management of major depression in outpatients attending a cancer centre: a preliminary evaluation of a multicomponent cancer nurse-delivered intervention. *British Journal of Cancer*. 2004;90(2):310-3.
96. Cuijpers P, van Straten A, Bohlmeijer E, Hollon S, Andersson G. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. *Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews* [Internet]: Centre for Reviews and Dissemination (UK); 2010.
97. Hunsley J, Elliott K, Therrien Z. The efficacy and effectiveness of psychological treatments for mood, anxiety, and related disorders. *Canadian Psychology/Psychologie canadienne*. 2014;55(3):161.

98. Cuijpers P, Clignet F, van Meijel B, van Straten A, Li J, Andersson G. Psychological treatment of depression in inpatients: A systematic review and meta-analysis. *Clinical psychology review*. 2011;31(3):353-60.
99. Cuijpers P, Kleiboer AM, DeRubeis RJ, Strunk DR. Self-directed approaches to the treatment of depression. In: *The Oxford handbook of mood disorders*. Oxford: Oxford University Press; 2017. p. 469-77.
100. Van't Hof E, Cuijpers P, Stein DJ. Self-help and Internet-guided interventions in depression and anxiety disorders: a systematic review of meta-analyses. *CNS spectrums*. 2009;14(2 Suppl 3):34-40.
101. Gyani A, Shafran R, Layard R, Clark DM. Enhancing recovery rates: lessons from year one of IAPT. *Behav Res Ther*. 2013;51(9):597-606.
102. McCusker, Cole MG, Yaffe M, Strumpf E, Sewitch M, Sussman T, et al. A randomized trial of a depression self-care toolkit with or without lay telephone coaching for primary care patients with chronic physical conditions. *General Hospital Psychiatry*. 2015;37(3):257-65.
103. Simco R, McCusker J, Sewitch M. Adherence to self-care interventions for depression or anxiety: A systematic review. *Health Education Journal*. 2014;73(6):714-30.
104. Donkin L, Christensen H, Naismith SL, Neal B, Hickie IB, Glozier N. A Systematic Review of the Impact of Adherence on the Effectiveness of e-Therapies. *J Med Internet Res*. 2011;13(3):e52.
105. Schulz KF, Grimes DA. Sample size slippages in randomised trials: exclusions and the lost and wayward. *Lancet (London, England)*. 2002;359(9308):781-5.
106. Nunan D, Aronson J, Bankhead C. Catalogue of bias: attrition bias. *Bmj Evidence-Based Medicine*. 2018;23(1):21-2.
107. Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. *BMJ (Clinical research ed)*. 2006;332(7547):969-71.
108. Warden D, Rush AJ, Carmody TJ, Kashner TM, Biggs MM, Crismon ML, et al. Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. *J Psychiatr Pract*. 2009;15(2):113-24.
109. Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN, et al. Predictors of attrition during initial (citalopram) treatment for depression: a STAR\*D report. *The American journal of psychiatry*. 2007;164(8):1189-97.
110. Lambert SD, Clover K, Pallant JF, Britton B, King MT, Mitchell AJ, et al. Making Sense of Variations in Prevalence Estimates of Depression in Cancer: A Co-Calibration of Commonly Used Depression Scales Using Rasch Analysis. *J Natl Compr Canc Netw*. 2015;13(10):1203-11.
111. van Grieken RA, Kirkenier ACE, Koeter MWJ, Schene AH. Helpful self-management strategies to cope with enduring depression from the patients' point of view: a concept map study. *BMC Psychiatry*. 2014;14:331-.
112. van Grieken RA, Kirkenier AC, Koeter MW, Nabitz UW, Schene AH. Patients' perspective on self-management in the recovery from depression. *Health Expect*. 2015;18(5):1339-48.
113. Michie S, Johnston M, Francis J, Hardeman W, Eccles M. From Theory to Intervention: Mapping Theoretically Derived Behavioural Determinants to Behaviour Change Techniques. *Applied Psychology*. 2008;57(4):660-80.

## Appendix

### Appendix A

#### Table 4

*Depression self-management skills included in the interventions*

	Barley et al. (2014)	Boele et al. (2018)	Espahbodi et al. (2015)	Fischer et al. (2015) & Schroder et al. (2014)*	Lamers et al. (2010)	Lee et al. (2014)	Moncrief et al. (2016)	Penckofer et al. (2012)	Rees et al. (2016)	Sharpe et al. (2004), Sharpe et al. (2014), Strong et al. (2008), & Walker et al. (2014)†	Thorton et al. (2009)	Total
<b>Decision-Making</b>	1	1	0	1	1	0	1	0	1	1	1	8
Often occurs in the context of problem-solving and is based on having enough and appropriate information to meet common changes associated with chronic illness (25).												
<b>Problem-solving</b>	1	1	1	1	1	0	1	0	1	1	1	9
Using a structured approach and learning skills such as problem definition, generating solutions, implementation, and evaluation of results to move towards a solution (25, 29).												
<b>Resource Utilization</b>	1	0	0	0	0	1	0	0	0	0	0	2
Learning how to seek out many resources (using different sources) (25).												
<b>Forming Partnerships with HCPs</b>	0	0	0	0	1	0	1	0	0	0	0	2
Learning how to provide disease-related feedback to HCPs and make informed treatment decisions and discuss with HCPs (25).												
<b>Taking Action</b>	1	1	0	1	1	0	1	0	1	1	0	7
Making a plan and carrying it out, learning skills involved in behaviour change (25).												
<b>Behavioural Activation</b>	0	0	0	1	0	0	1	1	0	0	0	4
Learning to gradually increase positive activities through effective goal setting (29)												
<b>Cognitive Restructuring</b>	0	1	0	1	1	0	1	1	0	0	0	5
Learning to identify depressive self-talk, challenge it, and												

come up with fair-realistic ways of evaluating situations (29).												
<b>Self-Monitoring</b>	1	0	0	0	1	0	1	1	1	0	0	5
Monitoring depression symptoms and evaluating whether current strategies are working effectively and, when necessary, reassessing treatment plans (57).												
<b>Health Habits</b>	0	0	0	1	0	1	1	1	0	0	1	5
Learning about the links between health habits (e.g., sleep, diet) and mental health. Learning how to enact helpful health related habits (58, 59).												
<b>Communicating about Depression</b>	0	0	0	0	0	0	0	1	0	0	0	1
Learning to explain what it means to experience depression to family members, friends, and colleagues (111).												
<b>Social Support</b>	1	1	0	1	0	1	1	1	0	0	1	7
Arranging instrumental and emotional support (111-113). Involving close friends/family in treatment and support (111, 112).												
<b>Relaxation</b>	0	0	1	1	0	1	1	1	0	0	1	6
Maintaining or developing activities related to relaxation (e.g., meditation, breathing exercises).												
<b>Self-tailoring</b>	1	1	0	0	1	0	1	1	1	1	0	7
Learning to use other SM skills based on a personal evaluation of your own needs.												
<b>Total</b>	7	6	2	8	7	4	11	8	6	4	5	

\*Fischer et al. (2015) and Schroder et al. (2014) delivered the same intervention to different disease populations. † Intervention delivered by Sharpe et al. (2004), Sharpe et al. (2014), Strong et al. (2008), & Walker et al. (2014) identically reported in terms of content and SM skills. Delivered to different oncology samples and some change reported in the interventionists.

## Appendix B

## Appendix C

Funnel Plots for Depression (primary outcome)

## Appendix D

Table 5

Quality Assessment of Included Studies

	Barley et al., 2014	Boele et al., 2018	Espahbodi et al., 2015	Fischer et al., 2015	Lamers et al., 2010ab; 2011	Lee et al., 2014	Moncrief et al., 2016	Penckofer et al., 2012	Rees et al., 2017	Schröder et al., 2014	Sharpe et al., 2004	Sharpe et al., 2014	Strong et al., 2008
Inclusion criteria specified	1	1	1	1	1	1	1	1	1	1	1	1	1
Pre-specified primary and secondary outcomes	1	1	1	1	1	1	1	1	1	1	1	1	1
Psychometric properties provided	0	1	1	0	0	0	1	1	1	1	1	1	1
Explicit power calculation	0	1	0	1	1	1	1	1	0	1	1	1	1
Target sample size reached	0	0	0	0	1	1	0	0	1	0	1	1	1
Randomization method specified and truly random	1	1	0	1	1	0	0	1	1	1	0	1	1
Randomization - Allocation concealed	1	1	0	1	1	0	1	0	1	0	0	1	0
Potential co-interventions discussed	1	0	0	0	1	1	0	1	1	1	1	1	1
Outcome assessors blind	1	0	0	0	0	1	1	0	1	0	1	1	1
Participants blind to treatment allocation	0	0	0	0	0	1	0	0	0	0	0	0	0
Interventionists blind	1	0	0	0	0	1	0	0	0	0	0	0	0
Adherence > 75%	0	0	0	1	1	1	0	1	1	1	1	1	1
Intention-to-treat data analysis	0	1	0	1	1	0	1	1	0	1	0	1	1
Overall >80% of sample in primary data analysis	1	0	1	0	0	1	0	1	1	0	1	1	1
Reason for attrition stated	1	1	1	0	1	1	1	1	1	0	1	0	1
Baseline characteristics for both groups reported	1	1	1	1	1	1	1	1	1	1	1	1	1
Fidelity monitoring	1	1	0	1	1	1	0	1	1	1	1	1	1
Total (/17)	11	10	6	9	12	12	9	12	13	10	12	14	14


**Notes:** Score of 1 if criterion met; 0 if not met or information unavailable. Pilot studies given automatic 0 for explicit power calculation as aim of pilot studies is not establish efficacy or effectiveness. Pilot studies given 1 for target sample size reached if rationale was provided for sample size and this was met. Thornton et al. (2009) was a sub-group analysis of a larger trial. A post-hoc power calculation was not included; as such, this study was scored as 0 for both power calculation and target sample size reached. Randomization- allocation concealment criterion was met if the person conducting randomization was independent from the research team (e.g., data collection, analysis, development of project aims). For self-directed interventions, participants themselves were

considered to be outcome assessors and interventionists; as such, if participants in self-directed interventions were aware of their group allocation outcome assessors and interventionist were deemed not to be blind and given a 0 for these criteria. Criterion of overall >80% of sample in primary data analysis was based on the stated primary data collection time point. If no primary time point was specified, the first data collection point was used. Reasons for attrition stated was based on dropouts after randomization. For self-directed interventions, if adherence criterion was met, fidelity criterion was also considered to be met. Studies were considered to be of high methodological quality if 13-17 criteria were met, moderate quality if 8-12 were met, and low fewer than 8 were met.

## Appendix E

### Forest Plots of Secondary Outcomes

## Figures



**Figure 1**

PRISMA 2009 Flow Diagram




Figure 2

Forest Plot of Depression T1 - Baseline to < 6 months




Figure 3

Forest Plot Depression T2 ≤ 6 months post-baseline

Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R) <1996 to June 25, 2018>			
#	Search Statement	Results	Annotation
1	Depression/	77227	
2	depressive disorder/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/	67536	
3	(depress* or low mood or dysthymia*).kf,tw.	297911	
4	1 or 2 or 3	318989	
5	clinical trial/ or exp controlled clinical trial/	590743	
6	controlled clinical trials as topic/ or non-randomized controlled trials as topic/ or randomized controlled trials as topic/ or equivalence trials as topic/ or pragmatic clinical trials as topic/	113995	
7	control groups/ or cross-over studies/ or double-blind method/ or random allocation/ or single-blind method/	212242	
8	Therapies, Investigational/	1260	
9	(random* or mask* or rct or rcts or blind* or assign* or cross over or crossover or pragmatic or quasi experiment* or wait list or waitlist or delayed treatment group or control* trial* or control* group* or clinical trial* or non-inferior* or noninferior*).kf,tw.	1545388	
10	5 or 6 or 7 or 8 or 9	1857311	
11	self care/ or self-management/	25390	
12	Self-Help Groups/	5612	
13	behavior therapy/	13901	
14	health education/ or patient education as topic/	89427	
15	Decision Making/	65100	
16	Problem Solving/	14796	
17	(self care* or self manage* or self regul* or self help* or self direct* or self monitor* or psychoeducation* or psycho education* or behavio?r therap* or CBT or decision making or problem solv* or resource utiliz* or partner* with health care provider* or partner* with health care professional* or tak* action or action plan* or goal set* or behavi?r activat* or cognitive restructur*).kf,tw.	182862	
18	11 or 12 or 13 or 14 or 15 or 16 or 17	331345	
19	4 and 10 and 18	7279	

Figure 4

Sample Search Strategy from Ovid Medline conducted June 25th, 2018




Figure 5

Funnel plot of intervention effect estimates for individual studies for depression at T1 - Baseline to < 6 months




Figure 6

Funnel plot of intervention effect estimates for individual studies for depression at T2 -  $\geq$  6 months post-baseline




Figure 7

Forest Plot of Anxiety T1 - Baseline to < 6 months




Figure 8

Forest Plot of Anxiety T2  $\geq$  6 months post-baseline




Figure 9

Forest Plot of MCS T1 - Baseline to < 6 months




Figure 10

Forest Plot of MCS T2  $\geq$  6 months post-baseline




Figure 11

Forest Plot of PCS T1 - Baseline to < 6 months




Figure 12

Forest Plot of PCS T2  $\geq$  6 months post-baseline




Figure 13

Forest Plot of Fatigue T1 - Baseline to < 6 months




Figure 14

Forest Plot of Glycemic Control T1 - Baseline to < 6 months




Figure 15

Forest Plot of Glycemic Control T2 ≥ 6 months post-baseline

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [BMCPsychiatryPRISMA2009checklist.doc](#)
- [CoverletterBMCPsychiatry.docx](#)